Objective: to select the optimal, clinically and economacally effective immunocorrector for the treatment of immune-EBV — mononucleosis in children. Materials: 400 patients with primary Epstein — Barr virus infection aged 1 to 14 years. Results. The therapy by cycloferon of primary Epstein — Barr virus infection observed a statistically significant reduction in the length of stay of patients in hospital, on average, 3 bed-days. Inclusion of cycloferon, viferon in the treatment of infectious mononucleosis, reduces the severity and duration of symptoms of intoxication, the temperature reaction, hepatotoxicity, splenomegaly, lymphoproliferative syndrome. Against the background of cycloferon lower incidence of post-infection anemia was observed. Conclusion. The inclusion of immunocorrectors into therapeutic interventions in primary Epstein — Barr virus infection has been clinically and economically proved.
Shvedova N.M., Mikhailova E.V., Tseka Y.S., Chudakova Т.К. Infectious mononucleosis in children: clinical and laboratory rationale and economic efficiency of application of immunocorrectors // Saratov Journal of Medical Scientific Research, Vol. 9, Issue 3, 2013, pp. 512-517

The research results are presented in the work. 100 patients aged 1–18 with different Epstein-Barr viral infection course variations have been observed. Clinical features of infectious mononucleosis in case of primary infection and its revivification have been revealed. The evaluation of intensity of autosensibilization processes has been performed. The interrelation of autoimmune and cytokine reactions and their participation in formation of organopathology in case of Epstein-Barr viral infection are demonstrated.
S.A. Khmilevskaya, I.A. Zaytseva, E.V. Mikhaylova Epstein-Barr Viral Infection in Children: Cytokine Response Peculiarities and Immunopathological Reactions // Saratov Journal of Medical Scientific Research, Vol. 5, Issue 2, 2009, pp. 222-226